Crinetics Pharmaceuticals Inc (CRNX)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
R. Scott Struthers
Employees:
47
10222 BARNES CANYON ROAD, BLDG. #2, SAN DIEGO, CA 92121
858-450-6464

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors.

Data derived from most recent annual or quarterly report
Market Cap 950.98 Million Shares Outstanding38.564 Million Avg 30-day Volume 274.694 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-1.39
Price to Revenue0.0 Debt to Equity0.0 EBITDA-88.026 Million
Price to Book Value3.6086 Operating Margin0.0 Enterprise Value523.163 Million
Current Ratio17.733 EPS Growth0 Quick Ratio17.096
1 Yr BETA 1.2339 52-week High/Low 28.78 / 12.77 Profit Margin0.0
Operating Cash Flow Growth-34.1301 Altman Z-Score26.5076 Free Cash Flow to Firm -62.543 Million
View SEC Filings from CRNX instead.

View recent insider trading info

Funds Holding CRNX (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding CRNX BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

1.2 Million total shares from 1 transactions

Open Market Sells (S)

48 Thousand total shares from 9 transactions

Exercise Derivative Conversion (M)

115.3 Thousand total shares from 2 transactions

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

BETZ STEPHEN F. CHIEF SCIENTIFIC OFFICER

  • Officer
148,879 2021-12-01 7

FUST MATTHEW K

  • Director
24,628 2021-11-01 6

MADAN AJAY CHIEF DEVELOPMENT OFFICER

  • Officer
184,671 2021-10-28 3

PERCEPTIVE ADVISORS LLC

PERCEPTIVE LIFE SCIENCES MASTER FUND LTD

EDELMAN JOSEPH

  • 10% Owner
5,163,517 2021-10-25 2

STRUTHERS RICHARD SCOTT PRESIDENT & CEO

  • Officer
  • Director
1,165,805 2021-09-07 2

KNIGHT JEFF E. CHIEF OPERATING OFFICER

  • Officer
160,000 2021-09-01 2

WIERENGA WENDALL

  • Director
17,500 2021-06-22 1

BEDROSIAN CAMILLE L

  • Director
17,500 2021-06-22 1

OKEY STEPHANIE

  • Director
17,500 2021-06-22 1

NICHOLS WESTON

  • Director
17,500 2021-06-22 1

KRASNER ALAN SETH CHIEF MEDICAL OFFICER

  • Officer
125,000 2021-02-26 2

WILSON MARC CFO AND SECRETARY

  • Officer
114,000 2021-02-26 2

KALDOR STEPHEN W

  • Director
0 2020-06-19 0

VIVO CAPITAL VIII, LLC

VIVO CAPITAL FUND VIII, L.P.

VIVO CAPITAL SURPLUS FUND VIII, L.P.

  • 10% Owner
No longer subject to file 2020-04-15 0

VIVO CAPITAL VIII, LLC

VIVO CAPITAL FUND VIII, L.P.

VIVO CAPITAL SURPLUS FUND VIII, L.P.

VIVO OPPORTUNITY, LLC

VIVO OPPORTUNITY FUND, L.P.

  • 10% Owner
3,266,090 2020-03-09 0

5AM VENTURES IV, L.P.

5AM CO-INVESTORS IV, L.P.

5AM PARTNERS IV, LLC

ROCKLAGE SCOTT M

DIEKMAN JOHN D

SCHWAB ANDREW J.

  • FORMER 10% HOLDERFORMER 10% HOLDERFORMER 10% HOLDERFORMER 10% HOLDERFORMER 10% HOLDERFORMER 10% HOLDER
No longer subject to file 2019-06-21 0

NIELSEN JACK

  • Director
0 2019-06-21 0

VERSANT VENTURE CAPITAL V, L.P.

VERSANT AFFILIATES FUND V, L.P.

VERSANT OPHTHALMIC AFFILIATES I, L.P.

VERSANT VENTURE CAPITAL V (CANADA), LP

VERSANT VENTURES V, LLC

VERSANT VENTURES V (CANADA), L.P.

  • 10% Owner
2,876,688 2019-02-04 0

VERSANT VENTURE CAPITAL V, L.P.

VERSANT AFFILIATES FUND V, L.P.

VERSANT OPHTHALMIC AFFILIATES I, L.P.

VERSANT VENTURE CAPITAL V (CANADA), LP

  • 10% Owner
6,298,477 2018-07-20 0

VIVO CAPITAL VIII, LLC

VIVO CAPITAL, LLC

VIVO CAPITAL FUND VIII, L.P.

VIVO CAPITAL SURPLUS FUND VIII, L.P.

VIVO OPPORTUNITY, LLC

VIVO OPPORTUNITY FUND, L.P.

  • 10% Owner
10,035,939 2018-07-20 0

ORBIMED ADVISORS LLC

ORBIMED CAPITAL GP VI LLC

  • 10% Owner
0 2018-07-17 0

VIVO CAPITAL VIII, LLC

VIVO CAPITAL, LLC

VIVO CAPITAL FUND VIII, L.P.

VIVO CAPITAL SURPLUS FUND VIII, L.P.

  • 10% Owner
54,711 2018-07-17 0

FREEMAN MASON

  • Director
0 2018-07-17 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

BETZ STEPHEN F. - Officer CHIEF SCIENTIFIC OFFICER

2021-12-03 16:36:33 -0500 2021-12-01 S 5,668 $27.38 d 148,879 direct yes

BETZ STEPHEN F. - Officer CHIEF SCIENTIFIC OFFICER

2021-11-17 17:01:06 -0500 2021-11-16 S 1,500 $27.97 d 154,547 direct yes 0.8136 -9.7633 1.6272 5 -9.7633 6

BETZ STEPHEN F. - Officer CHIEF SCIENTIFIC OFFICER

2021-11-17 17:01:06 -0500 2021-11-15 S 5,668 $26.75 d 156,047 direct yes 0.8136 -9.7633 1.6272 5 -9.7633 6

BETZ STEPHEN F. - Officer CHIEF SCIENTIFIC OFFICER

2021-11-09 17:44:59 -0500 2021-11-08 S 3,900 $28.42 d 161,715 direct yes -0.1825 0.0365 0.6569 5 -1.8978 3

BETZ STEPHEN F. - Officer CHIEF SCIENTIFIC OFFICER

2021-11-09 17:44:59 -0500 2021-11-05 S 12,600 $27.95 d 165,615 direct yes -0.1825 0.0365 0.6569 5 -1.8978 3

FUST MATTHEW K - Director

2021-11-03 16:55:44 -0400 2021-11-01 M 8,954 d 12,092 direct yes

BETZ STEPHEN F. - Officer CHIEF SCIENTIFIC OFFICER

2021-11-03 16:57:15 -0400 2021-11-01 S 5,668 $24.79 d 178,215 direct yes 1.0138 -0.9776 1.8103 4 -0.9776 6

FUST MATTHEW K - Director

2021-11-03 16:55:44 -0400 2021-11-01 S 8,954 $25.50 d 12,536 direct 1.0138 -0.9776 1.8103 4 -0.9776 6

FUST MATTHEW K - Director

2021-11-03 16:55:44 -0400 2021-11-01 M 8,954 $1.91 a 21,490 direct yes 1.0138 -0.9776 1.8103 4 -0.9776 6

MADAN AJAY - Officer CHIEF DEVELOPMENT OFFICER

2021-11-01 19:11:16 -0400 2021-10-28 M 106,383 d 0 direct

MADAN AJAY - Officer CHIEF DEVELOPMENT OFFICER

2021-11-01 19:11:16 -0400 2021-10-28 M 106,383 $0.73 a 184,671 direct 3.5687 6.7578 6.7578 6 0.0 1

BETZ STEPHEN F. - Officer CHIEF SCIENTIFIC OFFICER

2021-10-28 17:00:25 -0400 2021-10-27 S 3,000 $24.00 d 183,883 direct yes 8.0626 11.9134 11.9134 6 0.0 1

PERCEPTIVE ADVISORS LLC - > 10% Owner see footnote

PERCEPTIVE LIFE SCIENCES MASTER FUND LTD - > 10% Owner see footnote

EDELMAN JOSEPH - > 10% Owner see footnote

2021-10-25 14:47:16 -0400 2021-10-25 P 1,200,000 $19.80 a 5,163,517 indirect 9.2712 24.262 24.262 6 0.0 1

BETZ STEPHEN F. - Officer CHIEF SCIENTIFIC OFFICER

2021-10-25 16:28:18 -0400 2021-10-21 S 1,042 $21.10 d 186,883 direct yes 0.802 11.1862 13.7189 5 0.0 1

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
CRINETICS PHARMACEUTICALS IN CRNX 2021-12-03 22:15:03 UTC -0.18 0.25 800000
CRINETICS PHARMACEUTICALS IN CRNX 2021-12-03 21:45:03 UTC -0.18 0.25 800000
CRINETICS PHARMACEUTICALS IN CRNX 2021-12-03 21:15:04 UTC -0.18 0.25 800000
CRINETICS PHARMACEUTICALS IN CRNX 2021-12-03 20:45:03 UTC -0.18 0.25 800000
CRINETICS PHARMACEUTICALS IN CRNX 2021-12-03 20:15:03 UTC -0.18 0.25 800000
CRINETICS PHARMACEUTICALS IN CRNX 2021-12-03 19:45:03 UTC -0.18 0.25 800000
CRINETICS PHARMACEUTICALS IN CRNX 2021-12-03 19:15:04 UTC -0.18 0.25 800000
CRINETICS PHARMACEUTICALS IN CRNX 2021-12-03 18:45:04 UTC -0.18 0.25 800000
CRINETICS PHARMACEUTICALS IN CRNX 2021-12-03 18:15:03 UTC -0.18 0.25 800000
CRINETICS PHARMACEUTICALS IN CRNX 2021-12-03 17:45:03 UTC -0.18 0.25 800000
CRINETICS PHARMACEUTICALS IN CRNX 2021-12-03 17:15:03 UTC -0.18 0.25 800000
CRINETICS PHARMACEUTICALS IN CRNX 2021-12-03 16:45:03 UTC -0.2371 0.3071 800000
CRINETICS PHARMACEUTICALS IN CRNX 2021-12-03 16:15:04 UTC -0.2371 0.3071 800000
CRINETICS PHARMACEUTICALS IN CRNX 2021-12-03 15:45:03 UTC -0.2371 0.3071 800000
CRINETICS PHARMACEUTICALS IN CRNX 2021-12-03 15:15:03 UTC -0.2371 0.3071 800000
CRINETICS PHARMACEUTICALS IN CRNX 2021-12-03 14:45:03 UTC -0.202 0.272 800000
CRINETICS PHARMACEUTICALS IN CRNX 2021-12-03 14:15:05 UTC -0.202 0.272 800000
CRINETICS PHARMACEUTICALS IN CRNX 2021-12-03 13:45:03 UTC -0.202 0.272 800000
CRINETICS PHARMACEUTICALS IN CRNX 2021-12-03 13:15:03 UTC -0.202 0.272 800000
CRINETICS PHARMACEUTICALS IN CRNX 2021-12-03 12:45:03 UTC -0.202 0.272 800000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin
FundVantage Trust- Gotham Enhanced Index Plus Fund CRNX -7.0 shares, $-102.9 2020-03-31 N-PORT
FundVantage Trust- Gotham Index Plus All-Cap Fund CRNX -4.0 shares, $-58.8 2020-03-31 N-PORT

Elevate your investments